GRECCAR2 Trial: Details Worthy of More Attention
Huixun Jia,Yun Guan,Ji Zhu
DOI: https://doi.org/10.1016/s0140-6736(18)30015-1
2018-01-01
Abstract:We read with great interest the GRECCAR 2 trial by Eric Rullier and colleagues (July 29, 2017, p 469),1Rullier E Rouanet P Tuech JJ et al.Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.Lancet. 2017; 390: 469-479Summary Full Text Full Text PDF PubMed Scopus (189) Google Scholar which reported that local excision showed no superiority over total mesorectal excision in rectal cancer patients with a good response after chemoradiotherapy. However, some aspects of the study warrant closer attention. First, it is insufficient to determine yc tumour stage by MRI only. A meta-analysis showed that endoscopic ultrasound had better specificity than MRI (86% vs 69%).2Bipat S Glas AS Slors FJM Zwinderman AH Bossuyt PM Stoker J Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis.Radiology. 2004; 232: 773-783Crossref PubMed Scopus (801) Google Scholar Therefore, endoscopic ultrasound was used in some studies to identify if patients should receive local excision.3Verseveld M de Graaf EJ Verhoef C et al.Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study).Br J Surg. 2015; 102: 853-860Crossref PubMed Scopus (137) Google Scholar, 4National Cancer Research Institute (NCRI) Colorectal Clinical Studies Group TREC Trial Protocol.A randomised phase II feasibility study to compare radical TME surgery versus short course preoperative radiotherapy with delayed local excision for treatment of early rectal cancer. 2010; (Protocol v 1.0. Sept 15) (accessed Aug 8, 2017)http://www.birmingham.ac.uk/Documents/college-mds/trials/bctu/trec/TREC-protocol-v1.pdfGoogle Scholar Regrettably, endoscopic ultrasound was not used in this trial,1Rullier E Rouanet P Tuech JJ et al.Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.Lancet. 2017; 390: 469-479Summary Full Text Full Text PDF PubMed Scopus (189) Google Scholar which meant about half of the patients in the local excision group were classed as ypT2–3 or R1 resection and received subsequent total mesorectal excision. Second, the definition of the primary endpoint in this study1Rullier E Rouanet P Tuech JJ et al.Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.Lancet. 2017; 390: 469-479Summary Full Text Full Text PDF PubMed Scopus (189) Google Scholar deserves further consideration. We do not agree that death, recurrence, surgical morbidity, and severe complications are equivalently weighted in terms of the primary endpoint. A better functional outcome of the superiority of local excision to total mesorectal excision should be based on non-inferior oncological outcomes. Finally, the per-protocol dataset might have been inappropriately defined. According to ICH-E9 guidelines, the per-protocol set should be a subset of the intention-to-treat set, after excluding those who violate inclusion criteria.5Lewis JA Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline.Stat Med. 1999; 18: 1903-1942Crossref PubMed Scopus (173) Google Scholar However, nine patients were crossed to the other group in the per-protocol analysis according to actual treatment, regardless of initial intention-to-treat group. We declare no competing interests. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trialWe failed to show superiority of local excision over total mesorectal excision, because many patients in the local excision group received a completion total mesorectal excision that probably increased morbidity and side-effects, and compromised the potential advantages of local excision. Better patient selection to avoid unnecessary completion total mesorectal excision could improve the strategy. Full-Text PDF GRECCAR2 trial: details worthy of more attention – Authors' replyWe thank Ji Zhu and colleagues, who made very appropriate and constructive comments on the French GRECCAR 2 trial.1 Full-Text PDF